Holen Sie sich die Stockscreener-App
88.23
2.93%
-2.16
Schlusskurs vom Vortag:
$90.39
Offen:
$89.71
24-Stunden-Volumen:
15,106
Relative Volume:
0.07
Marktkapitalisierung:
$853.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.98M
KGV:
-66.96
EPS:
-1.3177
Netto-Cashflow:
$-3.85M
1W Leistung:
-0.30%
1M Leistung:
+4.12%
6M Leistung:
+193.64%
1J Leistung:
+171.81%
1-Tages-Spanne:
$87.66
$89.83
1-Wochen-Bereich:
$81.72
$91.00
52-Wochen-Spanne:
$23.18
$123.75
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Firmenname
Bright Minds Biosciences Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie DRUG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DRUG
Bright Minds Biosciences Inc
|
87.66 | 879.69M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | BTIG Research | Buy |
| 2025-05-13 | Eingeleitet | TD Cowen | Buy |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-01-23 | Eingeleitet | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Bright Minds Biosciences Inc Aktie (DRUG) Neueste Nachrichten
Price-Driven Insight from (DRUG) for Rule-Based Strategy - Stock Traders Daily
Bright Minds reports positive Phase 2 results for epilepsy drug By Investing.com - Investing.com Nigeria
New epilepsy study tests drug for adults whose seizures resist treatment - Stock Titan
Volume Summary: How Bright Minds Biosciences Inc. stock performs in high volatility markets - Bộ Nội Vụ
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Bright Minds Biosciences Stock Topped the Market on Monday - MSN
Bright Minds Biosciences closes $175 million public offering By Investing.com - Investing.com Nigeria
Bright Minds Biosciences (NASDAQ:DRUG) Cut to "Sell" at Wall Street Zen - MarketBeat
Bright Minds Biosciences Raises US$175 Million in Share Offering to Advance CNS Drug Pipeline - TipRanks
Bright Minds prices $175M stock offering - MSN
Bright Minds Biosciences Reports Phase 2 BMB-101 Data: 73% Median Drop in Absence Seizures on EEG - MarketBeat
Bright Minds Biosciences Closes its US$175 Million Public Offering - marketscreener.com
McMillan Advises Bright Minds Bioscience on its USD$175 Million Prospectus Offering - McMillan LLP
Bright Minds Biosciences closes $175 million public offering - Investing.com
Bright Minds Biosciences Closes $175.1 Million Stock Offering - marketscreener.com
Bright Minds Biosciences Announces Closing of US$175 Million Public Offering - manilatimes.net
Star TribuneBright Minds Biosciences Announces Closing of US$175 Million Public Offering - FinancialContent
Bright Minds Biosciences Launches $175 Million Share Offering to Fund Neurology Drug Pipeline - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) launches $175M equity raise for trials - Stock Titan
Can Bright Minds Biosciences Inc. stock sustain free cash flow growthBreakout Watch & High Conviction Investment Ideas - ulpravda.ru
How Bright Minds Biosciences Inc. stock responds to policy changesWeekly Volume Report & Daily Oversold Bounce Ideas - Улправда
Bright Minds Biosciences slips after increased $175 mln stock sale - TradingView — Track All Markets
Bright Minds Biosciences Prices Upsized US$175 Million Public Offering and Ends ATM Program - TipRanks
Bright Minds Biosciences prices public offering at $90 per share By Investing.com - Investing.com Nigeria
Bright Minds Biosciences prices $175 million public offering By Investing.com - Investing.com Nigeria
Why Bright Minds Biosciences Inc. stock is popular among millennialsSector ETF Performance & AI-Driven Stock Forecast Models - Улправда
Bright Minds Biosciences stock price target raised to $147 by BTIG By Investing.com - Investing.com Canada
Bright Minds Biosciences prices public offering at $90 per share - Investing.com
Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock - The Manila Times
Bright Minds Biosciences announces pricing of upsized US$175 million public offering of common stock at $90.00 per share - marketscreener.com
Bright Minds Biosciences launches $100 million public offering - MSN
Bright Minds Biosciences Ends Equity Distribution Deal With Piper Sandler and Cantor - TipRanks
Form FWP BRIGHT MINDS BIOSCIENCES Filed by: BRIGHT MINDS BIOSCIENCES INC. - StreetInsider
Bright Minds Biosciences: Positive BREAKTHROUGH Study Data Warrants 'Strong Buy' Rating - Seeking Alpha
Crude Oil Down 2%; ISM Services PMI Surges In December - Benzinga
Why Did DRUG Stock Rocket 51% Today? - Asianet Newsable
Bright Minds Biosciences falls after $100 mln equity offering launched - TradingView — Track All Markets
Bright Minds Biosciences stock price target raised to $147 by BTIG - Investing.com Nigeria
Bright Minds Biosciences, Praxis Precision Medicines And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Bright Minds Biosciences launches $100 million public offering By Investing.com - Investing.com Nigeria
Bright Minds Biosciences Launches US$100 Million Public Offering to Fund CNS Drug Pipeline - TipRanks
Will Bright Minds Biosciences Inc. stock deliver shareholder value - ulpravda.ru
Bright Minds Biosciences: Analyzing the Surge - StocksToTrade
New Bright Minds Epilepsy Drug Cuts Seizures, Lifts Stock On Tuesday - Sahm
Bright Minds Biosciences Unveils Strong Phase 2 Data for BMB-101 in Drug-Resistant Seizure Disorders - TipRanks
Bright Minds Seizure Treatment Trial Wraps Up - timothysykes.com
Finanzdaten der Bright Minds Biosciences Inc-Aktie (DRUG)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):